Early Discharge Clinic Cuts Hospital Stay in Blood Cancers

AN EARLY discharge clinic for patients undergoing intensive treatment for haematological malignancies reduced average hospital length of stay by 40%, new research has shown. 

The quality improvement initiative found that patients enrolled in the specialised outpatient programme spent an average of 10.2 fewer days in hospital compared with historical controls. No unplanned readmissions occurred within 48 hours of discharge, and no outpatient deaths were recorded. 

Moving High-Acuity Cancer Care Out of Hospital 

Intensive treatments for haematological malignancies can require prolonged hospital admissions due to complications and the need for close monitoring, transfusions, and other supportive care. However, extended admissions may place pressure on hospital capacity and negatively affect patients’ quality of life. 

Researchers at Northwell Health Cancer Institute, New York, USA, therefore established an Early Discharge Clinic (EDC) designed to allow selected patients to leave hospital earlier while continuing to receive intensive outpatient monitoring and treatment. 

Patients with haematological malignancies were enrolled during 2023 and 2024. Eligibility for early discharge was determined by factors including clinical stability, supportive care requirements, and whether patients were able to attend frequent outpatient appointments. 

The programme was structured around nine operational pillars designed to support high-acuity outpatient care. Researchers assessed outcomes including clinic utilisation, blood product requirements, time to antimicrobial treatment, unplanned readmissions, mortality, and average hospital length of stay. 

Hospital Stay Reduced Significantly 

Overall, the programme recorded 191 enrolments involving 112 individual patients. Participants received a median of five structured outpatient evaluations following discharge, with most requiring blood product support. 

Implementation of the EDC was associated with a 10.2 day reduction in average hospital length of stay compared with historical controls. This represented a 39.7% reduction and was statistically significant. 

Researchers also examined whether patients could receive timely treatment for potentially serious complications outside the inpatient setting. 

Neutropenic fever occurred during 36 of the 191 enrolments. Amongst these cases, the median time to antimicrobial administration was 46 minutes, ranging from 6 to131 minutes. 

Importantly, there were no unplanned hospital readmissions within 48 hours of discharge. Eleven unplanned readmissions occurred within 7 days, while no outpatient mortality was recorded. 

A Potential Model for Outpatient Cancer Care 

The findings suggest that carefully selected patients receiving intensive treatment for haematological malignancies may be managed safely outside hospital when supported by a dedicated infrastructure capable of providing rapid assessment and treatment. 

Reducing inpatient stays could also help alleviate pressure on hospital beds while allowing patients to spend more time outside the hospital environment during treatment. 

However, researchers warn that the findings should be interpreted within the context of a quality improvement initiative at a single health system.  

Patients were specifically selected for early discharge based on clinical and logistical criteria, meaning the approach may not be suitable for all individuals undergoing treatment for haematological malignancies. Hospital length of stay was also compared with historical rather than concurrently enrolled controls. 

Nevertheless, the researchers conclude that the EDC provides a practical framework for reducing hospitalisation while maintaining timely access to high-acuity supportive care. 

The findings may support further evaluation of specialised early discharge programmes as healthcare systems seek safe and efficient approaches to delivering increasingly complex cancer care in outpatient settings. 

Reference 

Christina A et al. Early Discharge Clinic: A Quality Improvement Initiative to Create a Safe and Efficient Model for Intensive Outpatient Management of Hematologic Malignancies. JCO Oncol Pract. 2026.  

Featured image: peopleimages.com on AdobeStock